Clinical research of modified CAG regimen for the treatment of relapsed acute myeloid leukemia.
- Author:
Jun-Yue CHAI
1
;
Wen-Qi ZHENG
;
Na WEI
Author Information
1. Department of Hematology and Oncology, Beijing Sixth Hospital, Beijing 100007, China. docchui@sohu.com
- Publication Type:Clinical Trial
- MeSH:
Aclarubicin;
Antineoplastic Combined Chemotherapy Protocols;
Cytarabine;
Granulocyte Colony-Stimulating Factor;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
Treatment Outcome
- From:
Journal of Experimental Hematology
2009;17(4):1061-1063
- CountryChina
- Language:Chinese
-
Abstract:
The objective of study was to observe the efficacy and adverse events of modified CAG regimen in treating patients with relapsed acute myeloid leukemia. CAG regimen with prolongation of aclarubicin up to 7 days were used to treat 17 cases of relapsed acute myeloid. After 1 course of chemotherapy, the efficacy and adverse events were evaluated, patients who did not achieve remission were excluded from this regimen, patients who achieved remission were continuously given 1 course of CAG regimen. The results showed that out of 17 case 8 patients achieved complete remission (CR, 47.06%) and 5 patients achieved partial remission (PR, 29.14%). Most of these cases had slight adverse events which mainly were marrow suppression that could be tolerated, overall survival was 76.47%. In conclusion, treatment for relapsed acute myeloid leukemia with modified CAG regiment is safe and effective, and can provide conditions for allo-hematopoietic stem cell transplantation, but its long term efficacy needs to further study.
